Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase I

Treatment

Completed

18 and over

Pharmaceutical / Industry

MPC-6827-04-002
NCT00393965

Trial Description

Summary

Phase 1, Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases.

Eligibility Criteria

Inclusion Criteria:

Refractory Brain Metastases

At least 1 measurable intracranial lesion as defined by RECIST

ECOG less than or equal to 1

Adequate hematology/organ function

No baseline peripheral or central neuropathy above grade 1

Exclusion Criteria:

Hypersensitivity to Cremophor EL

Pregnant or Lactating

Spinal Cord Compression

Pre-existing dementia/cognitive disfunction

Require Neupogen or Neulasta to Maintain Neutrophil Count

Have Primary Brain Cancer

Have History of Ischemic Heart Disease

Have Diabetes

Trial Contact Information

Trial Lead Organizations/Sponsors

Myriad Pharmaceuticals, Incorporated

Margaret Yu, MD

Study Director

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00393965
Information obtained from ClinicalTrials.gov on July 16, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.